Page last updated: 2024-09-05

lenalidomide and Local Neoplasm Recurrence

lenalidomide has been researched along with Local Neoplasm Recurrence in 268 studies

Research

Studies (268)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	16 (5.97)	29.6817
2010's	139 (51.87)	24.3611
2020's	113 (42.16)	2.80

Authors

Authors	Studies
Chudej, J; Guman, T; Hlebaskova, M; Kucerikova, M; Sokol, J; Stasko, J; Stecova, N; Valekova, L	1
Despas, F; Gauthier, M; Icard, C; Mocquot, P; Nogaro, JC	1
Assal, A; Banerjee, R; Bumma, N; D'Souza, A; Estrada-Merly, N; Fraser, R; Gale, RP; Hagen, P; Holmberg, L; Hossain, NM; Kumar, S; Lazarus, HM; Lee, C; Mian, H; Miller, KC; Nagler, A; Nathan, S; Nishihori, T; Parrondo, RD; Pasvolsky, O; Patel, S; Qazilbash, MH; Rozovski, U; Schroeder, MA; Shah, N; Shargian-Alon, L; Usmani, SZ; Wang, T; Wirk, B; Yeshurun, M	1
Fan, Z; Feng, R; Guo, X; Huang, F; Liu, Q; Ning, X; Sun, J; Wei, Q; Wei, X; Wei, Y; Xu, N	1
Ali, SA; Biavati, L; Borrello, I; Ferguson, A; Gandhi, A; Gittelman, RM; Gocke, CB; Huff, CA; Imus, P; Johnson, S; Noonan, KA; Rudraraju, L; Sanders, C; Sidorski, A; Stevens, MA; Vignali, M; Ye, X; Zucchinetti, C	1
Bartlett, NL; Becker-Hapak, M; Berrien-Elliott, MM; Cashen, AF; Desai, S; Fehniger, TA; Fischer, A; Foster, M; Gomez, F; Griffith, M; Griffith, OL; Krysiak, K; Luo, J; Maddocks, K; Mosior, M; Schmidt, A; Skidmore, ZL; Wagner-Johnston, ND; Ward, JP; Watkins, MP	1
Heimberg, L; Knop, S	1
Abrisqueta, P; Banerjee, L; Briones, J; Burke, JM; Chang, YM; Cordoba, R; Diefenbach, C; Hirata, J; Jiang, Y; Kahl, BS; McMillan, A; Miall, F; Musick, L; Paulson, JN	1
Dimopoulos, MA; Kastritis, E; Terpos, E	1
Asawa, P; Chahine, Z; Lister, J; Sadashiv, S; Samhouri, Y; Vusqa, UT	1
Cohen, JB; Gerber, DG; Romancik, JT; Zhuang, T	1
Bruno, B; Caballero-Velázquez, T; Einsele, H; Fanin, R; Gahrton, G; García-Cadenas, I; Granell, M; Herrera, P; López-Corral, L; Nahi, H; Patriarca, F; Pérez-Simón, JA; Reguera, JL; Reinoso-Segura, M	1
Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K	1
Dimopoulos, MA; Lonial, S; Richardson, P	1
Bourhis, F; Davies, FE; Guyot, P; Saunders, E	1
Cahill, KE; Smith, SM	1
Bohl, SR; Bullinger, L; Conrad, T; Döhner, H; Dolnik, A; Gütschow, M; Haji, M; Keller, U; Krönke, J; Kull, M; Mertins, P; Müller, S; Ng, YLD; Popp, O; Ramberger, E; Steinebach, C; Walther, W	1
Chen, D; Chen, Y; Gao, J; Jia, Y; Tao, H; Wang, F; Wu, P; Zhou, Z	1
DeCosta, L; Dirnberger, F; Goldschmidt, H; Kumar, S; Nooka, AK; Spencer, A; Terpos, E; Weisel, K; Yusuf, A	1
Afrough, A; Bashir, Q; Champlin, RE; Delgado, R; Hosing, C; Kaufman, GP; Kebriaei, P; Lee, HC; Ma, J; Manasanch, EE; Murphy, R; Orlowski, RZ; Pasvolsky, O; Patel, KK; Popat, UR; Qazilbash, MH; Saini, N; Shpall, EJ; Srour, S; Thomas, SK; Ullah, MR; Weber, DM	1
Bachanek-Mitura, O; Chocholska, S; Czabak, O; Hus, M; Mlak, R; Muzyka-Kasietczuk, J; Szczyrek, M; Szudy-Szczyrek, A	1
Brillac, C; Fau, JB; Gaudel-Dedieu, N; Koiwai, K; Nguyen, L; Rachedi, F; Sebastien, B; Semiond, D; Thai, HT; van de Velde, H; Veyrat-Follet, C	1
Feng, L; Flowers, CR; Fowler, NH; Gallardo, M; Gouni, S; Gunther, JR; Hagemeister, FB; Lee, HJ; Marques-Piubelli, ML; Nastoupil, LJ; Neelapu, SS; Noorani, M; Parra, ER; Rodriguez, MA; Samaniego, F; Soto, LS; Strati, P; Vega, F; Westin, JR; Wistuba, II	1
Hidaka, M; Iida, H; Kada, A; Kagoo, T; Komeno, T; Miyata, Y; Nagai, H; Saito, AM; Sawamura, M; Sunami, K; Takezako, N; Yokoyama, A	1
Chung, W; Iida, S; Iwasaki, H; Kuroda, J; Kuwayama, S; Lee, K; Matsue, K; Matsumoto, M; Nishio, M; Sugiura, I; Sunami, K	1
Ailawadhi, S; Alegria, V; Chanan-Khan, AA; Chapin, D; LaPlant, BR; Moustafa, MA; Parrondo, RD; Paulus, A; Roy, V; Sher, T	1
Rajkumar, SV	1
Chambers, W; Dores, GM; Jones, SC; Nadeau Nguyen, M; Nayernama, A	1
Álvaro-Naranjo, T; Carnicero-González, F; Casanova-Espinosa, M; de la Cruz-Merino, L; de la Cruz-Vicente, F; Espejo-García, P; Fernández-Álvarez, R; Fernández-Román, I; Gálvez-Carvajal, L; García-Domínguez, DJ; Gómez-Codina, J; Guirado-Risueño, M; Gumà-Padrò, J; Hontecillas-Prieto, L; Jiménez-Cortegana, C; Labrador, J; Martín García-Sancho, A; Martínez-Banaclocha, N; Marylene, L; Navarro, M; Nogales-Fernández, E; Palazón-Carrión, N; Provencio-Pulla, M; Ríos-Herranz, E; Rodríguez-Abreu, D; Rodríguez-García, G; Rueda-Domínguez, A; Salar-Silvestre, A; Sánchez-Beato, M; Sánchez-Margalet, V	1
Gandolfi, S; McCaughan, GJ; Moore, JJ; Richardson, PG	1
Kodad, SG; Sabry, W; Wu, Y	1
Frascione, PMM; Novo, M; Paruzzo, L; Poletto, S; Vitolo, U	1
Kameoka, Y	1
Arcaini, L; Barilà, G; Belotti, A; Benvenuti, P; Cafro, A; Cartia, CS; Farina, F; Fazio, F; Ferretti, VV; Galli, M; Klersy, C; Mangiacavalli, S; Marcatti, M; Masoni, V; Mazza, R; Mina, R; Olivares, C; Pagani, G; Palumbo, M; Paris, L; Petrucci, MT; Pezzatti, S; Pompa, A; Soldarini, M; Zambello, R	1
Hou, JJ; Jia, HY; Qiu, HY; Wu, Y; Zhang, MD; Zhou, ML	1
Bæch-Laursen, C; Eskelund, CW; Favero, F; Grønbæk, K; Husby, S; Hutchings, M; Jerkeman, M; Jespersen, JS; Kolstad, A; Larsen, TS; Niemann, CU; Pedersen, LB; Räty, R; Weischenfeldt, J	1
Borsi, E; Bratosin, F; Cerbu, B; Costachescu, D; Negrean, RA; Potre, C; Potre, O; Samfireag, M; Secosan, C	1
Armand, P; Avigan, D; Bartlett, NL; Bitran, J; Brody, JD; Farooqui, M; Ghesquieres, H; Hamadani, M; Herrera, AF; Kanate, A; Kline, J; Kuruvilla, J; Marinello, P; Morschhauser, F; Moskowitz, CH; Ribrag, V; Schuster, SJ; Zinzani, PL	1
Karimi, Y; Phillips, TJ; Takiar, R	1
Collinge, AD; Driessens, G; Ensbey, KS; Furlan, SN; Hill, GR; Holmberg, LA; Koyama, M; Legg, SR; Minnie, SA; Nemychenkov, NS; Olver, SD; Schmidt, CR; Sekiguchi, T; Sester, DP; Spencer, A; Takahashi, S; Varelias, A; Waltner, OG; Zhang, P	1
Matsue, K; Murata, R; Nakao, S; Takamatsu, H; Ueda, M; Yamashita, T; Yoroidaka, T; Yoshihara, K; Yoshihara, S	1
Aktas Samur, A; Anderson, KC; Avet-Loiseau, H; Bazarbachi, AH; Corre, J; Fulciniti, M; Magrangeas, F; Minvielle, S; Moreau, P; Munshi, NC; Parmigiani, G; Perrot, A; Richardson, PG; Roncador, M; Samur, MK; Shammas, MA; Sperling, AS; Szalat, R; Thakurta, A	1
Engelhardt, M; Wäsch, R	1
Corvatta, L; Manieri, MV; Morè, S; Offidani, M; Olivieri, A	1
Maddocks, K; Nedved, A; Nowakowski, GS	1
Yang, C; Zhuang, JL	1
Garcia-Horton, V; Guyot, P; Lin, PL; Richter, J; Sievert, M; Singh, E; Taiji, R; Zhou, ZY	1
Beldi-Ferchiou, A; Briere, J; Casasnovas, RO; Claudel, A; Corront, B; De Colella, JS; Delfau-Larue, MH; Fruchart, C; Gaulard, P; Ghesquieres, H; Godard, N; Haioun, C; Jais, JP; Lazarovici, J; Morschhauser, F; Nicolas-Virelizier, E; Oberic, L; Perrot, A; Salles, G; Thieblemont, C; Tilly, H; Zamali, I	1
Bergsagel, PL; Meermeier, EW	1
Ding, K; Jiang, X; Wang, X; Yu, L	1
Bessou, A; Colin, X; De Nascimento, J; Gorsh, B; Landi, S; Leleu, X; Paka, P; Wang, PF	1
Katayama, S; Ota, M; Yamaga, M	1
Costa, B; Delforge, M; Dimopoulos, M; Facon, T; Hulin, C; Leleu, X; Manier, S; Mouro, J; Sturniolo, M; Weisel, K	1
Ginn, M; Strouse, C; Struble, E	1
Arroyo, CH; Beksac, M; Besemer, B; Bourhis, JH; Eikema, DJ; Engelhardt, M; Haenel, M; Hayden, PJ; Jost, E; Kröger, N; Kuball, J; Manier, S; Mateos, MV; Mclornan, D; Michieli, M; Moraleda, JM; Rabin, N; Schaap, N; Schönland, S; Schub, N; Schuermans, C; Tilmont, R; Wilson, KMO; Yakoub-Agha, I; Za, T; Zinger, N	1
Bu, X; Li, C; Wang, L; Zhang, X; Zhao, P; Zhu, D	1
Anderson, KC; Bladé, J; Dispenzieri, A; Durie, BG; Facon, T; Kumar, S; Laubach, JP; Lonial, S; Mateos, MV; Moreau, P; Munshi, N; O'Donnell, E; O'Gorman, P; Perrot, A; Raje, N; Richardson, PG; Rosiñol, L; Voorhees, P	1
Kuroda, Y	1
Gupta, N; Kapoor, S; Sharma, A	1
Nohgawa, M; Oka, S; Ono, K	2
Anderson, KC; Baz, R; Becker, PS; Chuma, S; Ghobrial, IM; Henrick, P; Hornburg, K; Laubach, J; Liu, CJ; Perez, RP; Redd, RA; Reyes, K; Richardson, PG; Robbins, MD; Sabbatini, P; Savell, A; Sklavenitis-Pistofidis, R; Zavidij, O	1
Agirrezabal, I; Campioni, M; Gonzalez-McQuire, S; Hajek, R; Jandova, P; Maisnar, V; Minarik, J; Pour, L; Spicka, I	1
Fuchida, SI; Hatsuse, M; Matsui-Maegawa, S; Murakami, S; Okano, A; Shimazaki, C; Shimura, K; Taminishi-Katsuragawa, Y	1
Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J	1
Eom, HS; Jung, KS; Kim, HJ; Kim, JS; Kim, K; Kim, SH; Lee, JJ; Lee, JO; Min, CK; Shin, HJ	1
Ando, K; Hata, T; Hourai, M; Imaizumi, Y; Kobayashi, Y; Miyazaki, Y; Niino, D; Ohshima, K; Sato, S; Sawayama, Y	1
Ando, K; Chiwata, M; Fujioka, M; Furumoto, T; Hata, T; Horai, M; Imaizumi, Y; Itonaga, H; Kasai, S; Kato, T; Miyazaki, Y; Moriuchi, Y; Nakashima, J; Sakamoto, H; Sato, S; Sawayama, Y; Taguchi, J; Toriyama, E; Yoshida, S	1
Berenson, JR; Eades, BM; Eshaghian, S; Ghermezi, M; Lim, S; Martinez, D; Moss, RA; Sanchez, A; Schwartz, G; Spektor, TM; Stampleman, L; Swift, RA; To, J; Turner, C; Vescio, R	1
Gunji, T; Katori, M; Masuoka, H; Nishiwaki, K; Suzuki, K; Yano, S	1
Cheesman, S; Cohen, OC; Fontana, M; Gillmore, JD; Hawkins, PN; Kyriakou, C; Lachmann, HJ; Mahmood, S; Martinez-Naharro, A; Popat, R; Rabin, N; Sachchithanantham, S; Shah, R; Sharpley, F; Wechalekar, AD; Whelan, CJ; Yong, K	1
Bahlis, NJ; Benboubker, L; Chiu, C; Cook, G; Dimopoulos, MA; Ho, PJ; Kaufman, JL; Kim, K; Krevvata, M; Leiba, M; Moreau, P; Okonkwo, L; Qi, M; Qin, X; San-Miguel, J; Takezako, N; Trivedi, S; Ukropec, J; White, DJ	1
Bai, JF; Feng, R; Han, HX; Li, JT; Liu, H; Wang, T; Zhang, CL	1
Altuntaş, F; Batgi, H; Dal, MS; Kızıl Çakar, M; Merdin, A; Yiğenoğlu, TN	1
Michel, RP; Monczak, Y; Sebag, M; Shustik, C; Waller, DD	1
Agis, H; Blank, A; Blau, IW; Chatterjee, M; Einsele, H; Engelhardt, M; Ferstl, B; Goldschmidt, H; Griese, J; Härtle, S; Jarutat, T; Peschel, C; Raab, MS; Röllig, C; Schub, N; Weirather, J; Weisel, K; Winderlich, M	1
Angelillo, P; Arcari, A; Bertoldero, G; Calimeri, T; Cecchetti, C; Ciceri, F; De Lorenzo, D; Di Rocco, A; Fabbri, A; Ferreri, AJM; Foppoli, M; Frezzato, M; Nonis, A; Perrone, S; Ponzoni, M; Re, A; Rusconi, C; Sassone, M; Scarano, E; Spina, M; Steffanoni, S; Stelitano, C; Tarantino, V; Volpetti, S; Zaja, F; Zambello, R	1
Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Matous, J; Pierceall, WE; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K; Talamo, G; Zafar, F	1
Ambarkhane, S; André, M; Dirnberger-Hertweck, M; Dreyling, M; Duell, J; Fingerle-Rowson, G; Gaidano, G; González Barca, E; Jurczak, W; Kalakonda, N; Liberati, AM; Maddocks, K; Nagy, Z; Obr, A; Salles, G; Tournilhac, O; Weirather, J	1
Advani, RH; Ansell, SM; Cescon, TP; Chang, JE; Cheema, PS; Dy, PA; Evens, AM; Gascoyne, RD; Habermann, TM; Hong, F; Kahl, BS; O'Brien, TE; Quon, A; Ranheim, EA; Winter, JN; Witzig, TE	1
Gonzalez-McQuire, S; Lebioda, A; Poenisch, W; Rieth, A; Schoehl, M; Singh, M; Steinmetz, HT	1
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J	1
Bojan, A; Dima, D; Iluta, S; Jitaru, C; Pasca, S; Petrushev, B; Piciu, D; Roman, A; Rus, I; Teodorescu, P; Tomuleasa, C; Zdrenghea, M	1
Anderson, LD; Biyukov, T; Casal, E; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Jenner, M; Moreau, P; Nguyen, TV; Pavic, M; Peluso, T; Richardson, P; Salomo, M; San-Miguel, J; Sonneveld, P; Srinivasan, S; Weisel, K; White, D; Yu, X	1
Agarwal, A; Amatangelo, MD; Bahlis, NJ; Chung, W; Neri, P; Parekh, S; Pierceall, WE; Rahman, A; Serbina, N; Siegel, DS; Thakurta, A; Van Oekelen, O; Young, M	1
Hoy, SM	1
Beksaç, M; Mikhael, J; Richardson, PG; Špička, I	1
Hu, S; Wang, W; Zhang, W; Zhang, Y; Zhou, D; Zou, D	1
van de Donk, NWCJ	1
Antier, C; Moreau, P; Touzeau, C	1
Aitchison, R; Bhatti, Z; Bird, SA; Boyd, K; Bygrave, C; Chander, G; Collings, F; Dungarwalla, M; Jenner, MW; Kishore, B; Kothari, J; Maouche, N; Offer, M; Peniket, A; Ramasamy, K; Robinson, R; Vallance, GD	1
Americo, AD; Arcuri, LJ	1
Cheesman, S; De-Silva, D; Kyriakou, C; Lawson, G; Mahmood, S; Papanikolaou, X; Popat, R; Rabin, N; Sachchithananthan, S; Sive, J; Wechalekar, A; Yong, K; Ziff, M	1
Altman, JK; Artz, AS; Bennett, JM; Cheema, PS; Claxton, DF; Komrokji, RS; List, AF; Litzow, MR; Luger, SM; Maciejewski, J; Mattison, RJ; McGraw, K; Schiffer, CA; Sun, Z; Tallman, MS; Verma, A; Wassenaar, TR	1
Chang, MH; Do, YR; Eom, HS; Jo, JC; Kang, KW; Kim, DS; Kim, JS; Kim, KH; Kim, SH; Koh, Y; Lee, HS; Lee, JH; Lee, JJ; Lee, JY; Lee, WS; Lee, YJ; Min, CK; Park, Y; Shim, H; Shin, DY; Yoon, SS	1
Bacovsky, J; Brozova, L; Capkova, L; Hajek, R; Heindorfer, A; Jelinek, T; Jindra, P; Jungova, A; Kessler, P; Krhovska, P; Machalkova, K; Maisnar, V; Minarik, J; Mistrik, M; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Skacel, T; Spicka, I; Stejskal, L; Stork, M; Straub, J; Sykora, M; Ullrychova, J	1
Barchnicka, A; Bednarczyk, M; Grosicka, O; Grosicki, S	1
Bohli, M; El Fida Noubbigh, G; Jaffel, H; Kochbati, L; Msadek, F; Tbessi, S	1
Abu Zaanona, MI; Patel, P	1
Amin, H; Avet-Loiseau, H; Bahlis, NJ; Casneuf, T; Chiu, C; Iida, S; Kobos, R; Krevvata, M; Lonial, S; Moreau, P; Plesner, T; Qi, M; Qin, X; Ramaswami, P; San-Miguel, J; Spencer, A; Sun, S; Trivedi, S; Ukropec, J; Usmani, SZ; Weisel, K	1
Chari, A; Delea, TE; Hagiwara, M; Kee, A; Madduri, D; Parikh, K; Pelletier, C	1
Aizpurua, F; Duarte, PJ; Fantl, D; Foncuberta, C; Garate, G; Giannini, E; Lopresti, S; Milone, J; Ochoa, P; Orlando, S; Riveros, D; Schutz, NP; Shanley, C; Yantorno, S; Zabaljauregui, S	1
Colson, K; Grayson, D; Laubach, JP; Masone, K; Mitsiades, CS; Redd, RA; Richardson, PG; Rosenblatt, JM; Tuchman, SA; Warren, D	1
Amit, I; Avivi, I; Ballan, M; Bornstein, C; Chubar, E; Cohen, YC; Dally, N; David, E; Ganzel, C; Gatt, ME; Gur, C; Jarchowcky-Dolberg, O; Laiba, M; Lavi, N; Li, B; Luttwak, E; Moshe, A; Nemets, A; Pasvolsky, O; Rouvio, O; Shlomi-Loubaton, S; Shpilberg, O; Shvetz, O; Tadmor, T; Vaxman, I; Wang, SY; Weiner, A; Zada, M	1
Delforge, M; Kint, N; Vlayen, S	1
Bauhuf, I; Blätte, TJ; Bohl, SR; Bullinger, L; Damm, F; Döhner, H; Dolnik, A; Heckl, D; Knödler, S; Krönke, J; Kull, M; Langer, C; Letai, A; Meyer, T; Miller, D; Röhner, L; Schmalbrock, LK; Szyska, M	1
Bertram, S; Dührsen, U; Ganser, A; Hüttmann, A; Ibach, S; Kroschinsky, F; Tometten, M	1
Karlin, L; Try, M	1
Berg, D; Comenzo, RL; Dispenzieri, A; Faller, DV; Kastritis, E; Kim, K; Kumar, A; Kwok, F; Landau, HJ; Liu, G; Merlini, G; Sanchorawala, V; Schönland, SO; Suzuki, K; Wechalekar, AD	1
Atenafu, EG; Gorospe, K; Liu, Q; Liyasova, M; Ma, B; McDonald, Z; Piza, G; Reece, D; Taylor, P; Trudel, S; Xu, X; Yang, L; Yao, C	1
Gajewska, M; Lorent, M; Rzepecki, P; Sawicki, W; Terlikowska-Brzósko, A; Wróbel, K	1
Alizadeh, H; Altai, E; Borbényi, Z; Csukly, Z; Dávid Tóth, A; Deák, B; Gaál-Weisinger, J; Hardi, A; Illés, Á; Kohl, Z; Kórád, K; Kosztolányi, S; Lengyel, Z; Lovas, S; Masszi, T; Mikala, G; Modok, S; Nagy, Z; Plander, M; Radványi, G; Rajnics, P; Réka Szita, V; Rencsik, A; Rottek, J; Schneider, T; Szaleczky, E; Szendrei, T; Varga, G; Váróczy, L	1
Er, J; Harrison, SJ	1
Besien, KV; Cohen, K; Fishkin, PAS; Karrison, TG; Kimball, AS; Kline, J; Major, A; Nattam, S; Petrich, AM; Rao, K; Rapoport, AP; Sleckman, BG; Smith, SM	1
Bernard, S; Casasnovas, RO; Copie-Bergman, C; Feugier, P; García-Sancho, AM; Ghesquieres, H; Gomes da Silva, M; Greil, R; Griolet, S; Grosicki, S; Haioun, C; Morschhauser, F; Renaud, L; Thieblemont, C; Trotman, J; van Eygen, K	1
Casasnovas, O; Ghosh, N; Katakam, S; Knapp, A; Lossos, IS; McCord, R; Mehta, A; Morschhauser, F; Nielsen, T; Palomba, ML; Salles, G; Stevens, D	1
Goldschmidt, H; Kellermann, L; Knauf, W; Kohnke, J; Merz, M; Poenisch, W; Tischler, HJ	1
Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajnics, P; Ro, S; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A	1
Chan, TSY; Kwong, YL; Mak, V	1
Baz, R; Benson, DM; Campana, F; Charpentier, E; Lendvai, N; Lesokhin, AM; Martin, T; Munster, P; Vij, R; Wack, C; Wolf, J	1
Witzig, TE	1
Bartlett, NL; Blum, KA; Christian, BA; Devine, SM; Fehniger, TA; Jaglowski, SM; Maly, JJ; Phelps, MA; Sexton, JL; Wagner-Johnston, ND; Wei, L; Zhu, X	1
Chen, X; Du, X; Gupta, N; Hanley, MJ; Hou, J; Hua, Z; Jin, J; Ke, X; Li, H; Li, J; Liu, J; Lu, J; Moreau, P; Richardson, PG; van de Velde, H; Wang, B; Wang, H; Wu, D; Xu, Y; Zhang, X; Zhou, D	1
Cohen, PL; Debonera, F; Kremer, B; Schuster, SJ; Tsai, DE	1
Bergh, J; Camarero Jiménez, J; Demolis, P; Garcia, I; Gisselbrecht, C; Laane, E; Ludwig, H; Martin, M; Moreau, A; Pignatti, F; Salmonson, T; Sancho-López, A; Tzogani, K	1
Bartlett, NL; Blum, KA; Cheson, BD; Hsi, ED; Jung, SH; Leonard, JP; Martin, P; Pitcher, B; Ruan, J; Shea, T; Smith, SE	1
Avet-Loiseau, H; Bahlis, NJ; Ben-Yehuda, D; Berg, D; Cavo, M; Chng, WJ; di Bacco, A; Esseltine, DL; Ganly, P; Kumar, S; Langer, C; Lin, J; Masszi, T; Moreau, P; Nagler, A; Palumbo, A; Pluta, A; Pour, L; Rajkumar, SV; Richardson, PG; San-Miguel, J; van de Velde, H; Viterbo, L	1
Blaedel, J; Dimopoulos, MA; Facon, T; Goldschmidt, H; Jakubowiak, A; Ludwig, H; Obreja, M; San-Miguel, J; Siegel, DS; Stewart, AK	1
Bacher, U; Betticher, D; Egger, T; Gössi, U; Jeker, B; Mansouri Taleghani, B; Novak, U; Pabst, T; Zander, T	1
Aishima, S; Ando, T; Kidoguchi, K; Kimura, S; Kojima, K; Kubota, Y; Kusaba, K; Nakamura, H; Sano, H; Takase, Y; Yokoo, M; Yoshimura, M	1
Blaedel, J; DeCosta, L; Goldschmidt, H; Leleu, X; Mateos, MV; Mikhael, J; Obreja, M; San-Miguel, J; Szabo, Z; Zhou, L	1
Bagot, M; Barete, S; Beylot-Barry, M; Bonnet, N; Bouabdallah, R; Dalle, S; Duval-Modeste, AB; Frison, E; Grange, F; Gros, A; Ingen-Housz-Oro, S; Joly, P; Maillard, A; Maubec, E; Merlio, JP; Mermin, D; Mortier, L; Pham-Ledard, A; Quereux, G; Ram-Wolff, C; Templier, I; Vergier, B; Vially, PJ	1
He, W; Min, X; Yang, X	1
Abadi, U; Bekadja, MA; Beksac, M; Berthou, C; Boccadoro, M; Borbényi, Z; Cavo, M; Černelč, P; Corso, A; Couturier, C; De Stefano, V; Dimopoulos, M; Durán, MS; Feys, C; Kochkareva, Y; Laane, E; Legiec, W; Lejniece, S; Louw, V; Masliak, Z; Mateos, MV; Mohty, M; Nemet, D; Pečeliūnas, V; Pedersen, RS; Potamianou, A; Salwender, H; Silva, J; Stankovic, S; Terpos, E; Thoret-Bauchet, F; Willenbacher, W	1
Till, BG	1
Chen, X; Feng, J; Gao, G; Shen, H; Tang, H; Xu, L; Zhang, N; Zheng, Y	1
Bouabdallah, K; Cartron, G; Fabiani, B; Houot, R; Le Gouill, S; Ménard, C; Morschhauser, F; Salles, G; Tarte, K; Thieblemont, C; Tilly, H	1
Ansell, SM; Colgan, J; Dueck, AC; Ernst, B; Ginos, BF; Habermann, TM; Johnston, PB; Kosiorek, HE; Leis, JF; Mikhael, JR; Nowakowski, GS; Padrnos, L; Porrata, L; Reeder, C; Toro, A; Witzig, TE	1
Betts, KA; Brun, A; Chen, C; Dimopoulos, MA; Lonial, S; Makenbaeva, D; Mekan, S; Richardson, PG; Signorovitch, JE; Sy, O; Weisel, K; Zichlin, ML	1
Andre, M; Bijou, F; Bonnet, C; Bouabdallah, K; Cartron, G; Casasnovas, RO; de Guibert, S; Feugier, P; Fruchart, C; Haioun, C; Houot, R; Le Gouill, S; Maerevoet, M; Molina, L; Moluçon-Chabrot, C; Morschhauser, F; Nicolas-Virelizier, E; Ruminy, P; Salles, GA; Tilly, H; Van Den Neste, E; Van Eygen, K; Van Hoof, A; Zachee, P	1
Craft, M; Crispin, P; Koo, RM; Lalloo, S	1
Bailly, S; Croizier, C	1
Figg, WD; Hill, E; Kazandjian, D; Korde, N; Landgren, O; Mailankody, S; Roschewski, M	1
Breitkreutz, I; Goldschmidt, H; Raab, M	1
Beauchesne, P; Cassoux, N; Chevrier, M; Chinot, O; Choquet, S; Ghesquieres, H; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Laadhari, M; Le Garff-Tavernier, M; Moluçon-Chabrot, C; Morschhauser, F; Nicolas-Virelizier, E; Savignoni, A; Schmitt, A; Soumelis, V; Soussain, C; Touitou, V; Turbiez, I	1
Alizadeh, H; Bátai, Á; Deák, B; Demeter, J; Illés, Á; Kosztolányi, S; Mikala, G; Nagy, Z; Pető, M; Plander, M; Schneider, T; Szendrei, T; Szomor, Á; Varga, G; Váróczy, L	1
Ashby, C; Begum, DB; Cairns, DA; Cook, G; Davies, FE; Drayson, MT; Ellis, S; Greaves, M; Gregory, WM; Jackson, GH; Johnson, D; Jones, JR; Kaiser, MF; Melchor, L; Morgan, GJ; Owen, RG; Pawlyn, C; Rasche, L; Sherborne, AL; Walker, BA; Wardell, C; Weinhold, N	1
Attal, M; Avet-Loiseau, H; Caillon, H; Decaux, O; Dejoie, T; Moreau, P	1
Cabeçadas, J; Flinn, IW; Fogliatto, LM; Fowler, NH; Fustier, P; Gribben, JG; Hong, X; Izutsu, K; Kalambakas, S; Leonard, JP; Liu, D; Moreira, C; Nowakowski, GS; Offner, F; Pinto, A; Re, F; Scheinberg, P; Scheliga, A; Trneny, M; Wu, C; Zhang, H; Zhu, J	1
Ahmadi, T; Arkenau, HT; Boccadoro, M; Cavenagh, J; Chen, D; Chiu, C; de Boer, C; Gay, F; Krejcik, J; Laubach, JP; Minnema, MC; Moreau, P; Perrot, A; Plesner, T; Richardson, PG; Schecter, JM	1
Argnani, L; Balzarotti, M; Broccoli, A; Casadei, B; Cascavilla, N; Castellino, C; Chiappella, A; Conconi, A; Cox, MC; Devizzi, L; Fama, A; Gaudio, F; Goldaniga, MC; Marasca, R; Marino, D; Monaco, F; Musuraca, G; Paolini, R; Patti, C; Rigacci, L; Romano, A; Tani, M; Tecchio, C; Visco, C; Zancanella, M; Zinzani, PL	1
Abbasi, T; Abbott, D; Cogle, CR; Drusbosky, L; Fullerton, A; Gutman, JA; Hammes, A; Hemenway, G; Jordan, CT; Miltgen, N; Pollyea, DA; Schatz, D; Singh, NK; Smith, C; Stevens, B; Vali, S; Wei, Q; Winters, A	1
Damato, B; Formaker, P; Geng, H; Hwang, J; Mannis, G; Munster, PN; Rubenstein, JL; Vu, K	1
Boise, LH; Gleason, C; Gupta, VA; Heffner, LT; Joseph, NS; Kaufman, JL; Lonial, S; Nooka, AK	1
Bergin, K; Bowen, KM; Couto, S; Guzman, R; Kalff, A; Khong, T; Mithraprabhu, S; Ren, Y; Reynolds, J; Spencer, A; Thakurta, A; Wang, M	1
Abril, L; Clapés, V; Gassiot, S; González, Y; Ibarra, G; Maluquer, C; Morgades, M; Motlló, C; Oriol, A; Ribera, JM	1
Kiesewetter, B; Lamm, W; Mayerhoefer, ME; Neuper, O; Raderer, M; Simonitsch-Klupp, I	1
Bruyer, A; Cartron, G; de Boussac, H; De Bruyne, E; Gourzones, C; Hose, D; Jourdan, M; Kassambara, A; Maes, A; Moreaux, J; Pasero, P; Robert, N; Seckinger, A; Vincent, L	1
Beaupre, DM; Dang, NH; Delioukina, M; Ghosh, N; Goy, A; Kingsley, E; Knapp, M; Morgan, DS; Munoz, J; Neuenburg, JK; Ping, J; Ramchandren, R; Ruan, J	1
Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF	1
Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S	1
Fujiwara, T; Fukuhara, N; Harigae, H; Ishizawa, K; Kato, H; Katsuoka, Y; Okitsu, Y; Onishi, Y; Takagawa, M	1
Amrein, PC; Attar, EC; Ballen, KK; Deangelo, DJ; Fathi, AT; Foster, J; Fraser, JW; McAfee, S; Neuberg, D; Steensma, DP; Stone, RM; Wadleigh, M	1
Ai, H; Cai, Z; Chen, F; Chen, N; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wortman-Vayn, H; Wu, D; Yu, L; Zhang, J; Zhou, DB	1
Alsina, M; Baz, R; Dalton, WS; Djulbegovic, B; Ho, VQ; Miladinovic, B; Nishihori, T; Ochoa-Bayona, JL; Patel, A; Shain, KH; Sullivan, DM	1
Chng, WJ; Durie, BG; Eom, HS; Goh, YT; Kim, JS; Kim, K; Lee, JH; Ong, KH; Tan, D; Teoh, G	1
Forsberg, PA; Mark, TM	1
Avet Loiseau, H; Bonnet, S; Debarri, H; Demarquette, H; Facon, T; Fouquet, G; Gay, J; Guidez, S; Herbaux, C; Hulin, C; Leleu, X; Michel, J; Miljkovic, D; Perrot, A; Serrier, C; Tardy, S	1
Alsina, M; Bensinger, W; Huang, M; Kavalerchik, E; Martin, T; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M	1
Czuczman, MS; Haioun, C; Li, J; Polikoff, J; Prandi, K; Reeder, CB; Tilly, H; Vose, JM; Witzig, TE; Zhang, L; Zinzani, PL	1
Cabanillas, F; Rivera-Rodriguez, N	1
Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A	1
Becker, PS; Bensinger, WI; Burwick, N; Green, DJ	1
Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH	1
Aurran-Schleinitz, T; Blaise, D; Bouabdallah, R; Broussais-Guillaumot, F; Chetaille, B; Coso, D; Esterni, B; Ivanov, V; Olive, D; Schiano, JM; Stoppa, AM	1
Baumann, T; Delgado, J; Montserrat, E; Santacruz, R	1
Flohr, A; Schuelper, N; Trümper, L; Wulf, GG	1
Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Reece, DE; Sun, HL; Trudel, S; Winter, A; Yeboah, E	1
Demopoulos, AM; Devoe, CE; Li, JY	1
Cheesman, S; D'Sa, S; Dickson, J; Khan, I; Popat, R; Rabin, N; Smith, D; Yong, K	1
Afrin, LB; Bentz, TA; Costa, LJ; Fanning, SR; Kistner-Griffin, E; Stephenson, J; Stuart, RK	1
Anglin, P; Atenafu, EG; Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Mikhael, JR; Reece, DE; Trudel, S	1
Caballero, D; Coiffier, B; d'Amore, F; Dearden, C; Federico, M; Gomes da Silva, M; Jäger, U; Morschhauser, F; Pettengell, R; Tilly, H; Trümper, L; Weidmann, E; Zinzani, PL; Zucca, E	1
Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E	1
Badillo, M; Cai, Q; Chen, Y; Huang, H; Jiang, W; Lin, T; Lopez, E; Romaguera, J; Wang, M; Zhang, L; Zhou, S; Zou, D	1
Argnani, L; Cox, MC; Devizzi, L; Di Rocco, A; Fabbri, A; Fattori, PP; Rigacci, L; Rossi, G; Storti, S; Tura, S; Vitolo, U; Zaccaria, A; Zaja, F; Zinzani, PL	1
Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L	1
Bátorová, A; Mistrík, M; Roziaková, L	1
Belch, A; Chua, N; Dueck, G; Finch, D; Johnston, J; Prasad, A; Reiman, T; Stewart, D; Toumishey, E; van der Jagt, R; White, D	1
Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG	1
Buske, C	1
Baladandayuthapani, V; Claret, LC; Davis, RE; Fanale, MA; Fayad, LE; Feng, L; Fowler, NH; Hagemeister, FB; Kwak, LW; McLaughlin, P; Muzzafar, T; Nastoupil, L; Neelapu, SS; Oki, Y; Orlowski, RZ; Rawal, S; Romaguera, JE; Samaniego, F; Shah, J; Tsai, KY; Turturro, F; Wang, M; Westin, JR	1
Choquet, S; Hoang-Xuan, K; Houillier, C; Martin-Duverneuil, N; Mokhtari, K; Navarro, S; Soussain, C; Touitou, V	1
Buquicchio, C; Capalbo, S; Cascavilla, N; Curci, P; Di Renzo, N; Ditonno, P; Falcone, A; Guarini, A; Iannitto, E; Mazza, P; Mele, G; Melpignano, A; Minoia, C; Palazzo, G; Palumbo, G; Pavone, V; Polimeno, G; Quarta, G; Reddiconto, G; Ria, R; Rizzi, R; Rossini, B; Specchia, G; Tarantini, G; Vacca, A	1
Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A	1
Coyle, M; Evens, AM; Kritharis, A; Sharma, J	1
Ai, H; Cai, Z; Chen, F; Chen, N; DeMarco, D; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wu, D; Yu, L; Zhang, J; Zhou, DB	1
Arikian, SR; Binder, G; Corvino, FA; Gibson, CJ; Hu, XH; Hussein, M; Milentijevic, D; Nagarwala, Y; Surinach, A; Usmani, SZ	1
Oza, A; Rajkumar, SV	1
Bay, JO	1
Rosen, ST; Siddiqi, T	1
Goy, AH; Skarbnik, AP	1
Andre, P; Benson, DM; Caligiuri, MA; Cohen, AD; Efebera, YA; Hofmeister, CC; Jagannath, S; Munshi, NC; Spitzer, G; Zerbib, R	1
Cheah, CY; Forbes, SG; Fowler, NH; Nastoupil, LJ; Neelapu, SS; Oki, Y	1
An, N; Chen, S; Hu, Y; Huang, Z; Li, X; Shen, M; Sun, W; Zhan, X; Zhang, J; Zhong, Y	1
Amatya, R; Belch, A; Dimopoulos, M; Gibson, CJ; Jacques, C; Moreau, P; Palumbo, A; San Miguel, J; Schey, S; Song, KW; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M	1
Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Giguere, JK; Johnson, J; Jung, SH; Leonard, JP; Pitcher, BN	1
Bucalossi, A; Cioffi Squitieri, N; Guerrini, S; Mazzei, FG; Mazzei, MA; Volterrani, L	1
Ichikawa, K; Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Sugimoto, K; Tomita, S; Wakabayashi, M	1
Brioli, A; Cavo, M; Mancuso, K; Martello, M; Pantani, L; Rizzello, I; Rocchi, S; Tacchetti, P; Terragna, C; Zamagni, E; Zannetti, BA	1
Facon, T	1
Burger, JA; Calin, G; Faderl, S; Falchi, L; Ferrajoli, A; Gao, H; Keating, MJ; O'Brien, S; Reuben, JM; Rezvani, K; Shaim, H; Ten Hacken, E; Van Roosbroeck, K; Vitale, C; Wang, X; Wierda, WG	1
Cai, Z; Chen, F; DeMarco, D; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wu, D; Yu, L; Zhang, J; Zhou, DB	1
Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A	1
Afanasyev, B; Alexeeva, J; Arcaini, L; Belada, D; Biyukov, T; Bravo, MC; Giza, A; Jurczak, W; Kaplanov, K; Kuliczkowski, K; Kuzmin, A; Lamy, T; Marks, R; Mayer, J; Milpied, N; Morschhauser, F; Patturajan, M; Radford, J; Rule, S; Stelitano, C; Thyss, A; Trněný, M; Trümper, L; Voloshin, S; Walewski, J	1
Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kalapanida, D; Kanellias, N; Kastritis, E; Migkou, M; Roussou, M; Terpos, E; Zagouri, F	1
Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S	1
Coelho, I; Esteves, GV; Esteves, S; Freitas, J; Geraldes, C; Gomes, F; João, C; Lúcio, P; Neves, M	1
Baertsch, MA; Fenk, R; Goerner, M; Goldschmidt, H; Graeven, U; Haenel, M; Hielscher, T; Hillengaß, J; Ho, AD; Hose, D; Jauch, A; Klein, S; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Martin, H; Merz, M; Nogai, A; Noppeney, R; Raab, MS; Reimer, P; Salwender, H; Scheid, C; Schlenzka, J; Schmidt-Hieber, M; Schmidt-Wolf, IG; Weisel, K; Wuchter, P	1
Cuzzocrea, S; Ferrero, S; Ghione, P; Marabese, A; Mian, M; Mondello, P; Pitini, V; Steiner, N; Willenbacher, W	1
Kovarikova, A; Kusenda, J	1
Kaufman, J; Laubach, J; Lonial, S; Mateos, MV; Reece, D; Richardson, P	1
Cartia, CS; Cazzola, M; Cocito, F; Corso, A; Ferretti, V; Klersy, C; Mangiacavalli, S; Pompa, A; Varettoni, M	1
Atenafu, EG; Chen, C; Chu, CM; Kotchetkov, R; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S	1
Arcari, A; Bertoldero, G; Calimeri, T; Cecchetti, C; Chiozzotto, M; Couto, S; Fabbri, A; Ferreri, AJ; Frezzato, M; Govi, S; Nonis, A; Ponzoni, M; Re, A; Ren, Y; Rocco, AD; Rusconi, C; Sassone, M; Scarfò, L; Spina, M; Stelitano, C; Zaja, F; Zambello, R	1
Cole, CE; Ervin-Haynes, A; Habermann, TM; Justice, G; Lam, W; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB	1
Bargou, RC; Einsele, H; Falk, K; Gerecke, C; Glasmacher, A; Knop, S; Liebisch, P; Maeder, U; Platzbecker, U; Sezer, O; Topp, MS; Vollmuth, C	1
Basile, FG	1
Adès, L; Boehrer, S; Eclache, V; Fenaux, P; Gardin, C; Leroux, G; Martiat, P	1
Bokemeyer, C; Honecker, F; Oechsle, K	1
Amoroso, B; Arcamone, M; Becchimanzi, C; Capobianco, G; Corazzelli, G; Crisci, S; De Filippi, R; De Rosa, V; Frigeri, F; Iaccarino, G; Lastoria, S; Marcacci, G; Pinto, A; Russo, F	1
Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S	1
Bizzari, JP; Jacques, C; Knight, RD; Tozer, A; Zeldis, JB	1
Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G	1
Gleason, C; Kaufman, J; Lonial, S	1
Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C; Taverna, C	1
Bhandari, M; Callander, N; Flinn, I; Gasparetto, C; Glass, J; Grosman, D; Hari, P; Krishnan, A; Kumar, SK; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Sahovic, EA; Shi, H; Webb, IJ; Wolf, JL	1
Kolonic, SO; Mandac, I	1
Aurran-Schleinitz, T; Blaise, D; Bouabdallah, R; Chetaille, B; Chuto, G; Coso, D; Fezoui, H; Ivanov, V; Rey, J; Schiano, JM; Stoppa, AM; Tabouret, E	1
Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Roussou, M; Terpos, E	1
Barnett, MJ; Broady, R; Connors, JM; Forrest, DL; Hamata, L; Hogge, DE; Mourad, YA; Nantel, SH; Narayanan, S; Nevill, TJ; Nitta, J; Power, MM; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL; Venner, CP	1
Bouabdallah, R; Buckstein, R; Czuczman, MS; Ervin-Haynes, AL; Guo, P; Haioun, C; Pietronigro, D; Polikoff, JA; Reeder, CB; Tilly, H; Vose, JM; Witzig, TE; Zinzani, PL	1
Bravo, ML; Dimopoulos, MA; Harousseau, JL; Knight, RD; Olesnyckyj, M; Rajkumar, SV; San-Miguel, JF; Siegel, D; Stadtmauer, EA; Weber, DM; Zeldis, JB	1
Attal, M; Beksaç, M; da Costa, FL; Davies, FE; Delforge, M; Dimopoulos, MA; Einsele, H; Hajek, R; Harousseau, JL; Ludwig, H; Mellqvist, UH; Morgan, GJ; Palumbo, A; San-Miguel, JF; Sonneveld, P; Zweegman, S	1
Adamia, S; Anderson, KC; Blotta, S; Cervi, D; Cholujova, D; Daley, JF; Delmore, J; Jakubikova, J; Klippel, S; Kong, SY; Kost-Alimova, M; Laubach, J; Leiba, M; Mitsiades, CS; Ooi, M; Richardson, PG; Sedlak, J	1
Benevolo, G; Berruti, A; Boccadoro, M; Bringhen, S; Caravita, T; Cavallo, F; Corradini, P; Gay, F; Guglielmelli, T; Montefusco, V; Offidani, M; Palumbo, A; Petrucci, MT; Piro, E; Rrodhe, S; Saglio, G	1
Ansell, SM; Habermann, TM; Inwards, DJ; Johnston, PB; Klebig, RR; LaPlant, B; Macon, WR; Micallef, IN; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Witzig, TE	1
Antonarakis, ES; Carducci, M; Drake, CG; Eisenberger, MA; Keizman, D; McNeel, DG; Smith, HA; Thoburn, CJ; Zabransky, DJ; Zahurak, M	1
Benson, DM; Byrd, JC; Chan, KK; Chen, CS; Chen, P; Farag, SS; Garr, CL; Grever, MR; Hade, EM; Hicks, WJ; Hofmeister, CC; Ji, J; Johnson, AJ; Kraut, EH; Lee, S; Liu, Z; Phelps, MA; Pichiorri, F; Rozewski, DM; Schaaf, LJ; Yang, X	1
Glasmacher, A; Gorschlüter, M; Schmidt-Wolf, IG; Schwamborn, K	1
Colman, H; Conrad, CA; de Groot, J; Dhamne, M; Giglio, P; Gilbert, MR; Groves, MD; Hess, KR; Ictech, SE; Kang, SL; Levin, VA; Liu, V; Loghin, M; Puduvalli, VK; Yung, WK	1
Adam, Z; Chovancová, J; Hájek, R; Klabusay, M; Koukalová, R; Krejčí, M; Mayer, J; Pour, L; Rehák, Z; Slaisová, R; Stehlíková, O; Szturz, P	1
Berenson, JR; Bravin, E; Cartmell, A; Chen, CS; Flam, M; Hilger, JD; Kazamel, T; Nassir, Y; Swift, RA; Vescio, R; Woliver, T; Yellin, O	1
Abboud, CN; Bernabe, N; Cashen, AF; DiPersio, JF; Monahan, R; Ramsingh, G; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P	1
Binder, G; Borrello, I; Durie, B; Hussein, M; Khan, Z; Pashos, C	1
Jung, W; Schroers, R; Zettl, F	1
Bernstein, ZP; Byrne, C; Chanan-Khan, A; Chrystal, C; Czuczman, MS; Goodrich, DW; Hernandez-Ilizaliturri, F; Lawrence, D; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Porter, CW; Spaner, D; Starostik, P; Takeshita, K; Wallace, P	1
Le Beau, MM; Olney, HJ	1
Chan, JK; Guo, HY; Husain, A; Teng, NN; Zhang, MM	1
Tariman, JD	1
Dimopoulos, MA; Kastritis, E; Mitsiades, CS; Richardson, PG	1
Albert, PS; Duic, JP; Figg, WD; Fine, HA; Kim, L; Ma, H; Royce, C; Tohnya, T; Zhang, W	1
Richards, TA; Thomas, SK; Weber, DM	1
Lonial, S	1
Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH	1
Cohen, EN; Estrov, Z; Faderl, S; Ferrajoli, A; Gao, H; Keating, MJ; Lee, BN; Li, C; O'Brien, SM; Reuben, JM; Schlette, EJ; Wen, S; Wierda, WG	1
Andritsos, LA; Awan, F; Blum, W; Byrd, JC; Chen, CS; Jarjoura, D; Johnson, AJ; Kefauver, C; Knight, RD; Lapalombella, R; Lehman, A; Lozanski, G; May, SE; Raymond, CA; Ruppert, AS; Smith, LL; Wang, DS	1

Reviews

45 review(s) available for lenalidomide and Local Neoplasm Recurrence

Article	Year
Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Male; Neoplasm Recurrence, Local; Pharmacovigilance; Prednisone; Rituximab; Thalidomide	2022
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma. Oncology research and treatment, 2021, Volume: 44, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local	2021
SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma. Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:8 Topics: Adult; Antineoplastic Agents; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local	2022
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Proteasome Inhibitors	2022
Follicular Lymphoma: a Focus on Current and Emerging Therapies Oncology (Williston Park, N.Y.), 2022, 02-08, Volume: 36, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Genetic Testing; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Morpholines; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Prednisone; Pyridones; Rituximab; Sulfonamides; Vincristine	2022
Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review. Annals of agricultural and environmental medicine : AAEM, 2022, Mar-21, Volume: 29, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local	2022
Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. British journal of haematology, 2022, Volume: 199, Issue:2 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors; United States	2022
Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer treatment reviews, 2022, Volume: 110 Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Rituximab; Vincristine	2022
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis. Haematologica, 2023, 03-01, Volume: 108, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Propensity Score	2023
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. Clinical therapeutics, 2019, Volume: 41, Issue:11 Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome	2019
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Tafasitamab: First Approval. Drugs, 2020, Volume: 80, Issue:16 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Approval; Drug Resistance, Neoplasm; European Union; Humans; Infusions, Intravenous; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; United States; United States Food and Drug Administration	2020
Isatuximab for the treatment of relapsed/refractory multiple myeloma. Expert opinion on biological therapy, 2020, Volume: 20, Issue:12 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Treatment Outcome	2020
Sequencing multiple myeloma therapies with and after antibody therapies. Hematology. American Society of Hematology. Education Program, 2020, 12-04, Volume: 2020, Issue:1 Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide	2020
Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. Future oncology (London, England), 2021, Volume: 17, Issue:9 Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Treatment Outcome	2021
Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis. Annals of hematology, 2021, Volume: 100, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Network Meta-Analysis; Progression-Free Survival; Recurrence	2021
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma. Current treatment options in oncology, 2018, 07-21, Volume: 19, Issue:9 Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Everolimus; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine; Young Adult	2018
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trial Journal of immunology research, 2018, Volume: 2018 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome	2018
[Daratumumab for multiple myeloma]. Bulletin du cancer, 2018, Volume: 105, Issue:11 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide	2018
[First-line treatment of multiple myeloma]. Der Internist, 2019, Volume: 60, Issue:1 Topics: Antineoplastic Agents; Bortezomib; Germany; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous	2019
Recent advances in the management of mantle cell lymphoma. Current opinion in oncology, 2013, Volume: 25, Issue:6 Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Child; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Patient Selection; Phosphatidylinositol 3-Kinases; Prognosis; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome	2013
New treatment options for chronic lymphocytic leukemia. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:6 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Humans; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Receptors, Antigen, B-Cell; Signal Transduction; Thalidomide	2014
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer treatment reviews, 2014, Volume: 40, Issue:9 Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Depsipeptides; Diphtheria Toxin; Doxorubicin; Folic Acid Antagonists; Histone Deacetylase Inhibitors; Humans; Immunoconjugates; Interleukin-2; Lenalidomide; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Peptides, Cyclic; Prednisolone; Recombinant Fusion Proteins; Stem Cell Transplantation; Thalidomide; Topoisomerase Inhibitors; Vincristine	2014
Pomalidomide for multiple myeloma. Expert review of hematology, 2014, Volume: 7, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide	2014
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2014, Volume: 27, Issue:5 Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide	2014
Current treatment landscape for relapsed and/or refractory multiple myeloma. Nature reviews. Clinical oncology, 2015, Volume: 12, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome	2015
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. The oncologist, 2015, Volume: 20, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide	2015
Waldenstrom macroglobulinemia: prognosis and management. Blood cancer journal, 2015, Mar-27, Volume: 5 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunoglobulin M; Lenalidomide; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia	2015
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation. Oncology (Williston Park, N.Y.), 2015, Volume: 29, Issue:4 Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Prognosis; Protein-Tyrosine Kinases; Purines; Quinazolinones; Randomized Controlled Trials as Topic; Recurrence; Sulfonamides; Thalidomide; Treatment Outcome	2015
Lenalidomide for mantle cell lymphoma. Expert review of hematology, 2015, Volume: 8, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Thalidomide	2015
Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literat International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Osteogenesis; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Thalidomide	2015
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. Expert review of hematology, 2016, Volume: 9, Issue:3 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors; Salvage Therapy; Thalidomide	2016
Maintenance therapy for multiple myeloma in the era of novel agents. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Flow Cytometry; Hematology; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2015
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. Vnitrni lekarstvi, 2016, Volume: 62, Issue:1 Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia	2016
Multiple myeloma, immunotherapy and minimal residual disease. Neoplasma, 2016, Volume: 63, Issue:5 Topics: Antineoplastic Agents; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Humans; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual	2016
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Expert opinion on biological therapy, 2016, Volume: 16, Issue:10 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors; Signaling Lymphocytic Activation Molecule Family; Thalidomide; Treatment Outcome	2016
Current multiple myeloma treatment strategies with novel agents: a European perspective. The oncologist, 2010, Volume: 15, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Decision Making; Decision Trees; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous	2010
Lenalidomide in multiple myeloma: current role and future directions. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Rate; Thalidomide	2010
Treatment of relapsed and refractory myeloma. Current hematologic malignancy reports, 2009, Volume: 4, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide	2009
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss medical weekly, 2010, Volume: 140 Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Plasma Cells; Pyrazines; Retreatment; Switzerland; Thalidomide	2010
Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leukemia research, 2007, Volume: 31, Issue:4 Topics: Chromosome Aberrations; Chromosomes, Human, Pair 5; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Thalidomide	2007
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. Clinical journal of oncology nursing, 2007, Volume: 11, Issue:4 Topics: Anorexia; Antineoplastic Agents; Apoptosis; Constipation; Diarrhea; Drug Eruptions; Drug Monitoring; Dyspnea; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Nurse's Role; Nursing Assessment; Oncology Nursing; Thalidomide; Thrombocytopenia; Thromboembolism; Treatment Failure	2007
Management of relapsed and relapsed refractory myeloma. Hematology/oncology clinics of North America, 2007, Volume: 21, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide	2007
Lenalidomide in multiple myeloma. Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:4 Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Thalidomide	2007
Multiple myeloma: novel approaches for relapsed disease. Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide	2007

Trials

92 trial(s) available for lenalidomide and Local Neoplasm Recurrence

Article	Year
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood, 2022, 03-31, Volume: 139, Issue:13 Topics: Brentuximab Vedotin; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Treatment Outcome	2022
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. The Lancet. Haematology, 2021, Volume: 8, Issue:12 Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Follicular; Male; Neoplasm Recurrence, Local; Treatment Outcome	2021
Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. Transplantation and cellular therapy, 2022, Volume: 28, Issue:5 Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation Conditioning; Transplantation, Homologous	2022
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Leukemia & lymphoma, 2022, Volume: 63, Issue:6 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Plasma Cell; Quality of Life; Thalidomide	2022
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma. CPT: pharmacometrics & systems pharmacology, 2022, Volume: 11, Issue:6 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide	2022
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. Hematological oncology, 2022, Volume: 40, Issue:4 Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Exanthema; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome	2022
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 09-01, Volume: 28, Issue:17 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Rituximab; Treatment Outcome	2022
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. Leukemia & lymphoma, 2023, Volume: 64, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local	2023
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study. British journal of haematology, 2023, Volume: 201, Issue:2 Topics: Aged; Cell Count; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Prognosis; Rituximab	2023
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 01-15, Volume: 26, Issue:2 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Patient Safety; Receptors, CXCR4; Survival Rate; Treatment Outcome	2020
Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. The European journal of health economics : HEPAC : health economics in prevention and care, 2020, Volume: 21, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Czech Republic; Dexamethasone; Disease-Free Survival; Drug Costs; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Quality-Adjusted Life Years; Registries	2020
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 05-15, Volume: 26, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Janus Kinase 1; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitriles; Pyrazoles; Pyrimidines; Survival Rate	2020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia, 2020, Volume: 34, Issue:7 Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Thalidomide	2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. The Lancet. Haematology, 2020, Volume: 7, Issue:5 Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome	2020
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation. Hematological oncology, 2020, Volume: 38, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate	2020
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia, 2020, Volume: 34, Issue:12 Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide	2020
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. The Lancet. Oncology, 2020, Volume: 21, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult	2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 09-01, Volume: 26, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Rituximab; Young Adult	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia, 2021, Volume: 35, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Thalidomide	2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-20, Volume: 39, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Epoetin Alfa; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Recombinant Proteins; Survival Rate	2021
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. Blood cancer journal, 2021, 02-05, Volume: 11, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat	2021
Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma. Blood cancer journal, 2021, 05-17, Volume: 11, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Lenalidomide; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Rituximab; Survival Analysis	2021
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. Leukemia, 2022, Volume: 36, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Physicians; Prognosis; Salvage Therapy; Survival Rate; Thalidomide	2022
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica, 2022, 07-01, Volume: 107, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Sirolimus; TOR Serine-Threonine Kinases; Transplantation, Autologous; Treatment Outcome	2022
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. Blood cancer journal, 2021, 08-20, Volume: 11, Issue:8 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival	2021
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood cancer journal, 2017, 04-21, Volume: 7, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide; Treatment Outcome	2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood, 2017, 06-22, Volume: 129, Issue:25 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide	2017
A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Panobinostat; Remission Induction; Thalidomide; Young Adult	2017
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. Journal of hematology & oncology, 2017, 07-06, Volume: 10, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; China; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Placebo Effect; Thalidomide	2017
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. The oncologist, 2017, Volume: 22, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide	2017
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Nov-01, Volume: 28, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Rituximab; Survival Rate; Thalidomide	2017
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood, 2017, 12-14, Volume: 130, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Proportional Hazards Models; Thalidomide	2017
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 03-10, Volume: 36, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Survival Analysis	2018
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. The Journal of investigative dermatology, 2018, Volume: 138, Issue:9 Topics: Aged; Aged, 80 and over; Biopsy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; France; Humans; Immunologic Factors; Leg; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Remission Induction; Skin; Skin Neoplasms; Survival Rate; Treatment Outcome	2018
An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood, 2018, 10-04, Volume: 132, Issue:14 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local	2018
A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Everolimus; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma; Male; Maximum Tolerated Dose; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult	2018
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer, 2018, 10-15, Volume: 124, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Survival Analysis; Time Factors; Treatment Outcome	2018
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. Leukemia, 2019, Volume: 33, Issue:3 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence	2019
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. JAMA oncology, 2018, 12-01, Volume: 4, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Oligopeptides; Progression-Free Survival; Remission Induction; Treatment Outcome	2018
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 04-01, Volume: 30, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; France; Humans; Intention to Treat Analysis; Intraocular Lymphoma; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Proof of Concept Study; Prospective Studies; Remission Induction; Rituximab	2019
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, 2019, Volume: 104, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clonal Evolution; Exome Sequencing; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; Remission Induction; Thalidomide; Treatment Outcome	2019
Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:5 Topics: Adolescent; Adult; Biomarkers, Tumor; Bortezomib; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Reagent Kits, Diagnostic; Transplantation, Autologous; Treatment Outcome; Young Adult	2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 05-10, Volume: 37, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Placebos; Rituximab	2019
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. British journal of haematology, 2019, Volume: 186, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival	2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Leukemia research, 2019, Volume: 81 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Computational Biology; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Predictive Value of Tests; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult	2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Cancer, 2019, 09-01, Volume: 125, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome	2019
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Leukemia & lymphoma, 2019, Volume: 60, Issue:9 Topics: Adaptor Proteins, Signal Transducing; Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dexamethasone; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; Proteomics; Ubiquitin-Protein Ligases	2019
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood, 2019, 09-26, Volume: 134, Issue:13 Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome	2019
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-15, Volume: 19, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Thalidomide; Treatment Outcome	2013
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia research, 2013, Volume: 37, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide	2013
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. Journal of hematology & oncology, 2013, Jun-19, Volume: 6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome	2013
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood, 2013, Oct-31, Volume: 122, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Remission Induction; Thalidomide; Treatment Outcome	2013
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Recurrence; Thalidomide; Treatment Outcome	2013
A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma. Bone marrow transplantation, 2014, Volume: 49, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Thalidomide; Transplantation Conditioning; Transplantation, Homologous	2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood, 2014, Mar-20, Volume: 123, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome	2014
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia & lymphoma, 2015, Volume: 56, Issue:3 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Thalidomide; Thrombocytopenia; Treatment Outcome	2015
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. British journal of haematology, 2015, Volume: 168, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Thalidomide; Treatment Outcome	2015
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Lenalidomide; Membrane Proteins; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Thalidomide	2014
Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget, 2014, Sep-15, Volume: 5, Issue:17 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Stem Cell Transplantation; Thalidomide	2014
Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer, 2015, Mar-01, Volume: 121, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Thalidomide	2015
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. The Lancet. Oncology, 2014, Volume: 15, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Rituximab; Thalidomide; Treatment Outcome	2014
Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment. International journal of hematology, 2015, Volume: 101, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; China; Dexamethasone; Disease-Free Survival; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Renal Insufficiency; Thalidomide	2015
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Sep-15, Volume: 21, Issue:18 Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Immune System; Immunoglobulin G; Immunotherapy; Killer Cells, Natural; Lenalidomide; Ligands; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, KIR; Thalidomide; Treatment Outcome	2015
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood, 2015, May-21, Volume: 125, Issue:21 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Purines; Quinazolinones; Rituximab; Thalidomide	2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide	2015
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Progression; Disease-Free Survival; Female; Heparin; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Risk Factors; Rituximab; Thalidomide; Thrombosis; Treatment Outcome	2015
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 05-15, Volume: 22, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome	2016
Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. BMC cancer, 2016, Jan-28, Volume: 16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome	2016
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. British journal of haematology, 2016, Volume: 173, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Treatment Outcome; Young Adult	2016
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. The Lancet. Oncology, 2016, Volume: 17, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Survival Analysis; Thalidomide; Treatment Outcome	2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantatio BMC cancer, 2016, Apr-25, Volume: 16 Topics: Adult; Aged; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2016
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. The Lancet. Haematology, 2017, Volume: 4, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Quality of Life; Thalidomide; Treatment Outcome	2017
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-20, Volume: 26, Issue:30 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Thalidomide	2008
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood, 2009, Apr-30, Volume: 113, Issue:18 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Thalidomide; Time Factors; Treatment Outcome	2009
Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors. Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:1 Topics: Adult; Antineoplastic Agents; Cisplatin; Compassionate Use Trials; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Thalidomide; Treatment Outcome	2010
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia, 2010, Volume: 24, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome	2010
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia, 2010, Volume: 24, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome	2010
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; International Agencies; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Thalidomide; Treatment Outcome; Young Adult	2011
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Analysis; Thalidomide; Treatment Outcome	2011
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia, 2011, Volume: 25, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Rituximab; Survival Rate; Thalidomide; Treatment Outcome; Vincristine	2011
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. The Prostate, 2012, Volume: 72, Issue:5 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigens, Surface; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Humans; Immunomodulation; Interleukin-8; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Thalidomide	2012
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Sep-01, Volume: 29, Issue:25 Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Drug Interactions; Humans; Lenalidomide; Maximum Tolerated Dose; Multiple Myeloma; Neoplasm Recurrence, Local; Sirolimus; Survival Rate; Thalidomide; Tissue Distribution; Treatment Outcome	2011
Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma. German medical science : GMS e-journal, 2011, Volume: 9 Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide	2011
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer, 2012, Jul-15, Volume: 118, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Thalidomide; Young Adult	2012
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia, 2012, Volume: 26, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Polyethylene Glycols; Prognosis; Prospective Studies; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide	2012
A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. Leukemia, 2013, Volume: 27, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Remission Induction; Thalidomide; Young Adult	2013
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Dec-01, Volume: 24, Issue:34 Topics: Adult; Aged; Antineoplastic Agents; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Thalidomide; Thrombocytopenia	2006
Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. Gynecologic oncology, 2007, Volume: 105, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Thalidomide	2007
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Dec-01, Volume: 13, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Thalidomide	2007
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer, 2008, Apr-01, Volume: 112, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide	2008
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 2008, Jun-01, Volume: 111, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Cytokines; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; T-Lymphocytes; Thalidomide	2008

Other Studies

132 other study(ies) available for lenalidomide and Local Neoplasm Recurrence

Article	Year
Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma. Annals of hematology, 2022, Volume: 101, Issue:1 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cohort Studies; Dexamethasone; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Slovakia	2022
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone marrow transplantation, 2022, Volume: 57, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous	2022
[Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2021, Aug-31, Volume: 41, Issue:9 Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous	2021
An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 12-15, Volume: 27, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; CD8-Positive T-Lymphocytes; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local	2021
How I treat relapsed multiple myeloma. Blood, 2022, 05-12, Volume: 139, Issue:19 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy	2022
Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:5 Topics: Aged; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pancytopenia; Thalidomide	2022
Re: Arcuri and Americo "Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis". Annals of hematology, 2022, Volume: 101, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Network Meta-Analysis	2022
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nature communications, 2022, 02-23, Volume: 13, Issue:1 Topics: ATPases Associated with Diverse Cellular Activities; Cell Cycle Proteins; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteomics; Ubiquitin-Protein Ligases; Up-Regulation	2022
Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report. Medicine, 2022, Mar-04, Volume: 101, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Gastroscopy; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome; Ultrasonography	2022
Carfilzomib 56 mg/m Leukemia & lymphoma, 2022, Volume: 63, Issue:8 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides	2022
Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplantation and cellular therapy, 2022, Volume: 28, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies	2022
SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood advances, 2022, 06-14, Volume: 6, Issue:11 Topics: Humans; Lenalidomide; Lymphoma, Follicular; Macrophages; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab	2022
Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years. Nagoya journal of medical science, 2022, Volume: 84, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome	2022
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment. International journal of hematology, 2022, Volume: 116, Issue:1 Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Japan; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome	2022
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. American journal of hematology, 2022, Volume: 97, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Risk Assessment; Transplantation, Autologous	2022
Association of Daratumumab Use With Ocular Events in a Case Series of US Adults. JAMA oncology, 2022, 08-01, Volume: 8, Issue:8 Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local	2022
Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach. Current oncology (Toronto, Ont.), 2022, 07-18, Volume: 29, Issue:7 Topics: Bortezomib; Dexamethasone; HIV Infections; Humans; Lenalidomide; Neoplasm Recurrence, Local; Plasmablastic Lymphoma	2022
[Standard treatment and future perspectives for follicular lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Quality of Life; Rituximab	2022
Lenalidomide attenuates IMQ-induced inflammation in a mouse model of psoriasis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 156 Topics: Animals; Disease Models, Animal; Imiquimod; Inflammation; Lenalidomide; Mice; Mice, Inbred BALB C; Neoplasm Recurrence, Local; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Psoriasis; Skin; Tumor Microenvironment	2022
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL. Leukemia, 2022, Volume: 36, Issue:12 Topics: Clonal Hematopoiesis; Hematopoiesis; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Thalidomide	2022
Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients. Current oncology (Toronto, Ont.), 2022, 11-08, Volume: 29, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide	2022
Divergent paths: management of early relapsed follicular lymphoma. Hematology. American Society of Hematology. Education Program, 2022, 12-09, Volume: 2022, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Rituximab	2022
TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice. The Journal of clinical investigation, 2023, 02-15, Volume: 133, Issue:4 Topics: Animals; Hematopoietic Stem Cell Transplantation; Immunity; Lenalidomide; Mice; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, IgG; Receptors, Immunologic; Stem Cell Transplantation; Transplantation, Autologous; Tumor Microenvironment	2023
Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone. Anticancer research, 2023, Volume: 43, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual; Prospective Studies	2023
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood, 2023, 04-06, Volume: 141, Issue:14 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chronic Disease; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous	2023
Carfilzomib, lenalidomide, and dexamethasone maintenance for multiple myeloma: when and for whom? The Lancet. Oncology, 2023, Volume: 24, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local	2023
Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre. British journal of haematology, 2023, Volume: 201, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Tertiary Care Centers; Thalidomide	2023
Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The oncologist, 2023, 03-17, Volume: 28, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local	2023
[Analysis of the efficacy and survival of ixazomib-containing regimens in patients with refractory and relapsed multiple myeloma]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022, 08-14, Volume: 43, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local	2022
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma. Cancer medicine, 2023, Volume: 12, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence	2023
Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant. The Journal of clinical investigation, 2023, 02-15, Volume: 133, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Lenalidomide; Mice; Multiple Myeloma; Neoplasm Recurrence, Local; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2023
Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma. Cancer medicine, 2023, Volume: 12, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Neutropenia; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Tumor Microenvironment; Vincristine	2023
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database. European journal of haematology, 2023, Volume: 111, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Delivery of Health Care; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies	2023
Fever, Pancytopenia, and Tender Erythematous Plaques in a Patient With Multiple Myeloma. JAMA dermatology, 2023, 07-01, Volume: 159, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Erythema; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pancytopenia; Thalidomide	2023
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis. Clinical lymphoma, myeloma & leukemia, 2023, Volume: 23, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chronic Disease; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome	2023
Acute auto-aggression syndrome following autologous hematopoietic stem cell transplant and lenalidomide for multiple myeloma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:7 Topics: Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous	2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT. Bone marrow transplantation, 2023, Volume: 58, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation, Autologous; Treatment Outcome	2023
Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report. Annals of hematology, 2023, Volume: 102, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Rituximab	2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. Haematologica, 2023, 11-01, Volume: 108, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local	2023
[Infection risks and prevention in patients with multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2023, Volume: 64, Issue:9 Topics: Antibodies; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors	2023
A Polyherbal Ashwagandha Formulation Exhibits Adjunctive Antitumor Efficacy Against U266 Myeloma Cells by Multi-Strategic Cytotoxic Effects: An Experimental Approach. Asian Pacific journal of cancer prevention : APJCP, 2023, Nov-01, Volume: 24, Issue:11 Topics: Antineoplastic Agents; Carcinogenesis; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local	2023
Successful Retreatment with Elotuzumab for Multiple Myeloma with Extramedullary Relapse while Being Treated with Lenalidomide and Dexamethasone. Pathology oncology research : POR, 2020, Volume: 26, Issue:3 Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Retreatment	2020
Ixazomib-induced Sweet's syndrome. Leukemia & lymphoma, 2019, Volume: 60, Issue:14 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Sweet Syndrome	2019
[Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2019, Volume: 60, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Transplantation, Autologous	2019
Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome	2020
Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma. Oncology research and treatment, 2020, Volume: 43, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Resistance, Neoplasm; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Plasmablastic Lymphoma; Prognosis; Remission Induction; Salvage Therapy	2020
Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience. Hematological oncology, 2020, Volume: 38, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Homologous	2020
Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide. Cancer medicine, 2020, Volume: 9, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Eosinophils; Female; Follow-Up Studies; Humans; Lenalidomide; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Retrospective Studies; Time Factors; Time-to-Treatment	2020
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. British journal of haematology, 2020, Volume: 189, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local	2020
[Lenalidomide, rituximab and dexamethasone for the treatment of recurrent/refractory or elderly newly diagnosed patients with primary central nervous system lymphoma: 5 cases report and literature review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2019, Dec-14, Volume: 40, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dexamethasone; Humans; Lenalidomide; Lymphoma; Neoplasm Recurrence, Local; Rituximab; Treatment Outcome	2019
A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Colitis, Ischemic; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous	2020
Spontaneous remission and clonal evolution in lenalidomide associated secondary AML. Leukemia & lymphoma, 2020, Volume: 61, Issue:7 Topics: Clonal Evolution; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Remission, Spontaneous	2020
Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany. Oncology research and treatment, 2020, Volume: 43, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Female; Germany; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Progression-Free Survival; Proteasome Inhibitors; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult	2020
Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab. International journal of hematology, 2020, Volume: 112, Issue:4 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Remission Induction; Rituximab; Treatment Outcome	2020
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 11-15, Volume: 26, Issue:22 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Proliferation; Dexamethasone; Female; Humans; Immunomodulation; Immunophenotyping; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; T-Lymphocytes, Regulatory; Thalidomide	2020
Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report. Medicine, 2020, Oct-23, Volume: 99, Issue:43 Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy	2020
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience. Leukemia & lymphoma, 2021, Volume: 62, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; United Kingdom	2021
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set. Leukemia & lymphoma, 2021, Volume: 62, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors	2021
Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. Annals of hematology, 2021, Volume: 100, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Progression-Free Survival; Republic of Korea	2021
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC cancer, 2021, Jan-15, Volume: 21, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Czech Republic; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Prospective Studies; Registries	2021
Elotuzumab in the treatment of relapsed and refractory multiple myeloma. Future oncology (London, England), 2021, Volume: 17, Issue:13 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Killer Cells, Natural; Lenalidomide; Mesenchymal Stem Cells; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide	2021
Synergistic Effect and Tolerance of Concurrent Radiotherapy and Lenalidomide Use in Relapsing Mantle Cell Lymphoma: A Case Report. The Permanente journal, 2020, Volume: 24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Neoplasm Recurrence, Local; Pyrimidines; Treatment Outcome	2020
Plasma cell leukaemia with t(11;14) not responsive to venetoclax. BMJ case reports, 2021, Jan-25, Volume: 14, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Oncogene Proteins, Fusion; Sulfonamides; Translocation, Genetic; Transplantation, Autologous; Treatment Failure	2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 04-01, Volume: 39, Issue:10 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual; Outcome Assessment, Health Care; Progression-Free Survival; Prospective Studies; Randomized Controlled Trials as Topic	2021
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future oncology (London, England), 2021, Volume: 17, Issue:5 Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Progression-Free Survival; Proteasome Inhibitors; Retrospective Studies; Thalidomide; United States	2021
Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from Expert review of hematology, 2021, Volume: 14, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Latin America; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies	2021
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nature medicine, 2021, Volume: 27, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Single-Cell Analysis; Treatment Outcome	2021
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts. Expert review of hematology, 2021, Volume: 14, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide	2021
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. Blood advances, 2021, 05-11, Volume: 5, Issue:9 Topics: CRISPR-Cas Systems; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pharmaceutical Preparations	2021
[New European approvals: Carfilzomib with daratumumab and dexamethasone in refractory or relapsed multiple myeloma after a first line of treatment]. Bulletin du cancer, 2021, Volume: 108, Issue:6 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Administration Schedule; Drug Approval; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Randomized Controlled Trials as Topic	2021
A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM). Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 09-15, Volume: 27, Issue:18 Topics: Humans; Lenalidomide; Mass Spectrometry; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual	2021
DRESS syndrome after KRd (carfilzomib, lenalidomide, dexamethasone) therapy in a patient with multiple myeloma. Polish archives of internal medicine, 2021, 10-27, Volume: 131, Issue:10 Topics: Dexamethasone; Drug Hypersensitivity Syndrome; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides	2021
Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers. Pathology oncology research : POR, 2021, Volume: 27 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Hungary; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome	2021
KRd: the new KiD in the French myeloma induction class. Blood, 2021, 07-15, Volume: 138, Issue:2 Topics: Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local	2021
Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. Blood advances, 2021, 08-10, Volume: 5, Issue:15 Topics: Central Nervous System; Humans; Incidence; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local	2021
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. Annals of hematology, 2017, Volume: 96, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Female; Germany; Health Surveys; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Transplantation, Autologous	2017
Complete radiologic and molecular response of HIV-negative primary effusion lymphoma with short-course lenalidomide. Annals of hematology, 2017, Volume: 96, Issue:7 Topics: Aged, 80 and over; DNA, Viral; Drug Eruptions; Drug Monitoring; Eosinophilia; Epstein-Barr Virus Infections; Gastrointestinal Stromal Tumors; Herpesvirus 4, Human; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Primary Effusion; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiography, Thoracic; Treatment Outcome; Tumor Burden	2017
Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 08-01, Volume: 35, Issue:22 Topics: Adult; Aged; Child; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Prednisone; Rituximab; Vincristine	2017
Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide. Leukemia & lymphoma, 2018, Volume: 59, Issue:3 Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission, Spontaneous; Withholding Treatment	2018
Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. Hematological oncology, 2018, Volume: 36, Issue:2 Topics: Adult; Aged; Autografts; Disease-Free Survival; Humans; Lenalidomide; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Thalidomide; Time Factors; Transplantation, Autologous	2018
Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide. Leukemia & lymphoma, 2018, Volume: 59, Issue:10 Topics: Cord Blood Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome	2018
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematological oncology, 2018, Volume: 36, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Thalidomide	2018
Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report. Medicine, 2018, Volume: 97, Issue:21 Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Lymphadenopathy; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Parotid Gland; Positron Emission Tomography Computed Tomography; Rituximab; Thalidomide; Transplantation, Autologous; Treatment Outcome	2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Prospective Studies; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome	2018
Successful treatment of central nervous system myeloma manifesting as cauda equina nodules with intrathecal chemotherapy, lenalidomide and dexamethasone. BMJ case reports, 2018, Nov-08, Volume: 2018 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Cauda Equina; Central Nervous System Neoplasms; Dexamethasone; Humans; Injections, Spinal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome	2018
Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program. Pathology oncology research : POR, 2019, Volume: 25, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glycine; Humans; Hungary; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Safety; Salvage Therapy; Survival Rate	2019
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. The oncologist, 2019, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Italy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Rituximab; Treatment Outcome	2019
Maintenance lenalidomide in primary CNS lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 08-01, Volume: 30, Issue:8 Topics: Humans; Intraocular Lymphoma; Lenalidomide; Lymphoma; Neoplasm Recurrence, Local; Prospective Studies; Rituximab	2019
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents? Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Disease Management; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Registries; Survival Analysis; Treatment Outcome; Young Adult	2019
Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna. Hematological oncology, 2019, Volume: 37, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Austria; Drug Evaluation; Female; Follow-Up Studies; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Retrospective Studies; Treatment Outcome	2019
Kinome expression profiling to target new therapeutic avenues in multiple myeloma. Haematologica, 2020, Volume: 105, Issue:3 Topics: Cell Cycle Proteins; Humans; Immunologic Factors; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Protein Serine-Threonine Kinases	2020
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood, 2013, Jun-06, Volume: 121, Issue:23 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult	2013
Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide. Annals of hematology, 2013, Volume: 92, Issue:12 Topics: Clarithromycin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome	2013
Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leukemia research, 2013, Volume: 37, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide	2013
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Leukemia research, 2013, Volume: 37, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Republic of Korea; Singapore; Survival Rate; Tertiary Care Centers; Thalidomide	2013
Pomalidomide in the treatment of relapsed multiple myeloma. Future oncology (London, England), 2013, Volume: 9, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide	2013
Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer, 2013, Oct-15, Volume: 119, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide	2013
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Feb-15, Volume: 20, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endothelial Cells; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Panobinostat; Proteome; Pyrazines; Reactive Oxygen Species; Thalidomide; Transcription, Genetic	2014
Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Leukemia & lymphoma, 2014, Volume: 55, Issue:11 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Retrospective Studies; Rituximab; Thalidomide; Thrombocytopenia; Treatment Outcome	2014
Osteolytic lesions in patients with relapse of diffuse large B-cell lymphoma treated with lenalidomide. Annals of hematology, 2014, Volume: 93, Issue:11 Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Neoplasm Recurrence, Local; Osteolysis; Radiography; Thalidomide; Treatment Outcome	2014
Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia & lymphoma, 2015, Volume: 56, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Thalidomide; Time Factors; Treatment Outcome	2015
The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide. Journal of neuro-oncology, 2014, Volume: 119, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Brain Neoplasms; Female; Humans; Lenalidomide; Neoplasm Recurrence, Local; Plasmacytoma; Thalidomide; Treatment Outcome	2014
An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma. British journal of haematology, 2015, Volume: 168, Issue:1 Topics: Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide	2015
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. Leukemia & lymphoma, 2015, Volume: 56, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Immunologic Factors; Italy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Off-Label Use; Retrospective Studies; Survival Rate; Thalidomide	2015
Towards a chemotherapy-free approach in indolent lymphoma. The Lancet. Oncology, 2014, Volume: 15, Issue:12 Topics: Antibodies, Monoclonal, Murine-Derived; Female; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Rituximab; Thalidomide	2014
Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. Neurology, 2015, Jan-20, Volume: 84, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Central Nervous System Neoplasms; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Thalidomide	2015
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese". Leukemia research, 2015, Volume: 39, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide	2015
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood, 2015, Apr-16, Volume: 125, Issue:16 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome	2015
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Current medical research and opinion, 2015, Volume: 31, Issue:6 Topics: Adult; Aged; Bortezomib; Costs and Cost Analysis; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide	2015
[Carfilzomib in multiple myeloma relapses]. Bulletin du cancer, 2015, Volume: 102, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Heart; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide	2015
[Clinical observations of lenalidomide combination chemotherapy for relapsing or refractory multiple myeloma]. Zhonghua yi xue za zhi, 2015, Mar-17, Volume: 95, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Beijing; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Remission Induction; Thalidomide	2015
Ischemic colitis diagnosed by magnetic resonance imaging during lenalidomide treatment in a patient with relapsed multiple myeloma. Tumori, 2016, Nov-11, Volume: 102, Issue:Suppl. 2 Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Colitis, Ischemic; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Heparin; Humans; Lenalidomide; Magnetic Resonance Imaging; Metronidazole; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome	2016
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. Leukemia & lymphoma, 2016, Volume: 57, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Thalidomide; Treatment Outcome	2016
Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment. Annals of hematology, 2016, Volume: 95, Issue:6 Topics: Aged; Aged, 80 and over; Cohort Studies; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Renal Insufficiency; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome	2016
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia. Prescrire international, 2016, Volume: 25, Issue:170 Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine	2016
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? The oncologist, 2016, Volume: 21, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Secondary Prevention; Thalidomide; Treatment Outcome	2016
The possible role of burden of therapy on the risk of myeloma extramedullary spread. Annals of hematology, 2017, Volume: 96, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Sarcoma, Myeloid; Survival Rate; Thalidomide	2017
Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. Cancer medicine, 2017, Volume: 6, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Thalidomide; Treatment Outcome	2017
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide. Leukemia & lymphoma, 2009, Volume: 50, Issue:4 Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Decitabine; Humans; Lenalidomide; Leukemia, Myeloid; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide	2009
Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission. Bone marrow transplantation, 2010, Volume: 45, Issue:4 Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 5; Female; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Thalidomide; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous	2010
Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. American journal of hematology, 2010, Volume: 85, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Compassionate Use Trials; Hodgkin Disease; Humans; Inflammation; Lenalidomide; Male; Neoplasm Recurrence, Local; Thalidomide; Young Adult	2010
Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma. Journal of hematology & oncology, 2010, May-28, Volume: 3 Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Lenalidomide; Neoplasm Recurrence, Local; Salvage Therapy; Thalidomide; Treatment Outcome; Young Adult	2010
Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma. Leukemia & lymphoma, 2010, Volume: 51, Issue:9 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Remission Induction; Rituximab; Salvage Therapy; Thalidomide	2010
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia, 2010, Volume: 24, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome	2010
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). Leukemia & lymphoma, 2011, Volume: 52, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Survival Rate; Thalidomide; Transplantation, Autologous; Young Adult	2011
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia, 2011, Volume: 25, Issue:5 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide	2011
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood, 2011, Apr-28, Volume: 117, Issue:17 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; ATP-Binding Cassette Transporters; Bone Marrow Cells; Cell Division; Cell Fractionation; Cell Line, Tumor; Cell Survival; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Signal Transduction; Stromal Cells; Syndecan-1; Thalidomide	2011
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:6 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Interactions; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome	2011
Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:3 Topics: Adult; Antineoplastic Agents; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide; Treatment Outcome	2012
Total cost comparison in relapsed/refractory multiple myeloma. Journal of medical economics, 2013, Volume: 16, Issue:5 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fees, Pharmaceutical; Health Expenditures; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide	2013
[Multiple myeloma -- therapy]. Deutsche medizinische Wochenschrift (1946), 2005, Feb-11, Volume: 130, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2005
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-20, Volume: 26, Issue:15 Topics: Adult; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Thalidomide; Tumor Cells, Cultured	2008